Related references
Note: Only part of the references are listed.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Treatment recommendations for psoriatic arthritis
C. T. Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
David L. Scott et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Golimumab, a Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis
Paul Emery et al.
ARTHRITIS AND RHEUMATISM (2009)
Adalimumab for the treatment of psoriatic arthritis
Denis A. Poddubnyy et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2009)
E-selectin, Interleukin 18, Serum Amyloid A, and Matrix Metalloproteinase 9 Are Associated with Clinical Response to Golimumab plus Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Sudha Visvanathan et al.
JOURNAL OF RHEUMATOLOGY (2009)
Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis
Cynthia S. Crowson et al.
JOURNAL OF RHEUMATOLOGY (2009)
Treatment of rheumatoid arthritis: we are getting there
Yusuf Yazici
LANCET (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Golimumab
Dimitrios A. Pappas et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists
Ernest Choy
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Robert D. Inman et al.
ARTHRITIS AND RHEUMATISM (2008)
TNFα blockade in human diseases:: Mechanisms and future directions
Maida Wong et al.
CLINICAL IMMUNOLOGY (2008)
Fully human antibodies from transgenic mouse and phage display platforms
Nils Lonberg
CURRENT OPINION IN IMMUNOLOGY (2008)
Emerging drugs for rheumatoid arthritis
Paraskevi V. Voulgari
EXPERT OPINION ON EMERGING DRUGS (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations
Y. Yazici et al.
RHEUMATOLOGY (2008)
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy
M. Bokarewa et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2007)
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment - Results from the induction and maintenance psoriatic arthritis clinical trial 2
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Daniel E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice:: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Consensus statement on the use of rituximab in patients with rheumatoid arthritis
J. S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs:: an observational study
Liisa Konttinen et al.
CLINICAL RHEUMATOLOGY (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
R. M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
J Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
SN Nikas et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Etanercept, infliximab and adalimiumb bind to soluble and transmembrane TNF with similar affinities.
Zehra Kaymakcalan et al.
CLINICAL IMMUNOLOGY (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Selective costimulation modulators - A novel approach for the treatment of rheumatoid arthritis
JM Kremer
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2005)
Feasibility of 1 hour infliximab infusions
RF van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement - A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
JS Smolen et al.
ARTHRITIS AND RHEUMATISM (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Cardiovascular Death in Rheumatoid Arthritis A Population-Based Study
Hilal Maradit-Kremers et al.
ARTHRITIS AND RHEUMATISM (2005)
Epidemiology of adult rheumatoid arthritis
Y Alamanos et al.
AUTOIMMUNITY REVIEWS (2005)
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor a blockade: comment on the article by Buch et al
MH Schiff
ARTHRITIS AND RHEUMATISM (2005)
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis - Five-year experience from the FIN-RACo trial
K Puolakka et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis
J van Aken et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
R Fleischmann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
C Grigor et al.
LANCET (2004)
Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis
MJ Peters et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2004)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis - 'DIP or not DIP revisited'
D Kane et al.
RHEUMATOLOGY (2003)
Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial
JC Davis et al.
ARTHRITIS AND RHEUMATISM (2003)
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
J Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis - A large, international, multicenter, placebo-controlled trial
RM Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2003)
Unproven hypothesis that leflunomide is better than methotrexate as measured by magnetic resonance imaging: comment on the article by Reece et al - Reply
P Emery et al.
ARTHRITIS AND RHEUMATISM (2003)
Prevalence of joint disease in patients with psoriasis - Implications for therapy
H Zachariae
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2003)
Glucocorticoids and rheumatoid arthritis - Back to the future?
LW Moreland et al.
ARTHRITIS AND RHEUMATISM (2002)
Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
J Braun et al.
LANCET (2002)
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies
LR Lard et al.
AMERICAN JOURNAL OF MEDICINE (2001)
The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis
B Bresnihan
SEMINARS IN ARTHRITIS AND RHEUMATISM (2001)
Infliximab - A review of its use in the management of rheumatoid arthritis
A Markham et al.
DRUGS (2000)
Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study
AA Drosos et al.
RHEUMATOLOGY INTERNATIONAL (2000)
Hyperuricemia in psoriatic arthritis - Prevalence and associated features
IN Bruce et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2000)
Share Paper
